{
    "nct_id": "NCT04280328",
    "official_title": "An Open-Label Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "* Relapsed or refractory myeloma.\n* Must have been exposed to at least 2 cycles of an IMiD containing regimen and PI containing regimen and must be refractory to at least one of the two.\n* Must have completed and tolerated 2 cycles of daratumumab or other anti-CD38 targeting antibodies.\n* Active myeloma requiring systemic treatment.\n* Measurable disease per protocol.\n* ECOG performance status of 0 - 2.\n* Life expectancy of at least 3 months.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* POEMS syndrome; non-secretory myeloma (no measurable protein on sFLC assay); amyloidosis.\n* History of select prior malignancies.\n* Previous intolerance to daratumumab or any study drug.\n* Received an allogeneic stem cell transplant within 12 months, or an autologous stem cell transplant within 6 months, or have ongoing toxicity related to transplant.\n* Have an active infection or serious comorbid medical condition.\n* Any live attenuated vaccination against infectious diseases (e.g., influenza, varicella) within 4 weeks of initiation of study treatment; uncontrolled human immunodeficiency virus, or positive tests for hepatitis B or hepatitis C.\n* Female participants pregnant or breast-feeding.\n* Screening chemistry and blood counts within protocol limits\n* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressant medication during study treatment.",
    "miscellaneous_criteria": ""
}